ASH 2021 | Targeting MDS stem cells with omacetaxine and azacitidine
Daniel Pollyea
• 10 Dec 2021
Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, shares findings from a Phase I trial (NCT03564873) looking at targeting myelodysplastic syndrome (MDS) stem cells with omacetaxine, protein synthesis inhibitor, and azacitidine, a hypomethylating agent (HMA). The trial demonstrated that the combination showed clinical activity in patients with high risk MDS, and a number of patients succeeded in allogeneic stem cell transplant. Dr Pollyea additionally highlights the Phase II portion of the trial, which will further assess efficacy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
